KimberlyPerezMD

Oncology • Providence, RI

Gastrointestinal Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Perez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Perez's full profile

Already have an account?

Office
593 Eddy St
Providence, RI 02903
Phone+1 401-444-8450

Fax+1 401-444-5088

Education & Training

Brown UniversityFellowship, Hematology and Medical Oncology, 2010
George Washington University School of Medicine and Health SciencesClass of 2004

Certifications & Licensure

MA State Medical License 2015 - 2026
RI State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Start of enrollment: 2014 Aug 01
Completed
Phase 2
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis Start of enrollment: 2013 May 01
Unknown status
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer Start of enrollment: 2018 Dec 05
Active, not recruiting
Phase 1, Phase 2
Cabozantinib and Nivolumab for Carcinoid Tumors Start of enrollment: 2019 Dec 26
Completed
Phase 2
Roles: Contact, Principal Investigator
LY3214996 +/- HCQ in Pancreatic Cancer Start of enrollment: 2020 May 27
Completed
Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
Recruiting
Phase 3
Roles: Contact
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Start of enrollment: 2023 Jan 06
Terminated
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Start of enrollment: 2023 Mar 22
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

41 citations
RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients
Sam Cross-Knorr, Shaolei Lu, Kimberly Perez, Sara Guevara, Kate E. Brilliant
BMC Cancer. 2013-10-08
196 citations
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.
Srivatsan Raghavan, Peter S Winter, Andrew W Navia, Hannah L Williams, Alan DenAdel
Cell. 2021-12-09
3 citations
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Ad...
Brandon M Huffman, Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S Kapner
Clinical Cancer Research. 2023-12-15

Journal Articles

Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic Cancer
Richard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature

Lectures

Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Dana-Farber Cancer Institute, Brigham and Women''s Hospital Designated as Rare Disease Clinical CenterJune 29th, 2022
Dana-Farber Cancer Institute/Brigham and Women’s Hospital Designated as Rare Disease Clinical Center for Pheochromocytoma &June 28th, 2022
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerJanuary 27th, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member